Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2893177 | 1.00 | GRM5 (0.47) | GRM5PKMMEN1NPC1ALDH1A1 | |
| SCHEMBL2893471 | 1.00 | GRM5 (0.47) | GRM5PKMMEN1NPC1ALDH1A1 | |
| SCHEMBL4051271 | 0.87 | GRM5 (0.48) | GRM5PKMMEN1NPC1ALDH1A1 | |
| SCHEMBL14363428 | 0.87 | GRM5 (0.48) | GRM5PKMMEN1NPC1ALDH1A1 | |
| SCHEMBL27770576 | 0.86 | PKM (0.48) | GRM5PKMMEN1NPC1ALDH1A1 | |
| SCHEMBL2895174 | 0.85 | GRM5 (0.47) | GRM5PKMMEN1NPC1ALDH1A1 | |
| SCHEMBL2001185 | 0.84 | GRM5 (0.46) | GRM5MEN1ALDH1A1LMNAGAA | |
| SCHEMBL3115514 | 0.84 | GRM5 (0.46) | GRM5MEN1ALDH1A1LMNAGAA | |
| SCHEMBL2002209 | 0.84 | GRM5 (0.46) | GRM5MEN1ALDH1A1LMNAGAA | |
| SCHEMBL27770577 | 0.83 | GRM5 (0.46) | GRM5PKMMEN1NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716125-B1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | ASTRAZENECA AB (SE) | 2013-06-19 | — | — | EP | disclosed |
| CN-1918137-B | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2012-08-01 | — | — | CN | disclosed |
| CN-101845023-A | Tetrazole compound and as the application of metabotropic glutamate receptor antagonists | NPS PHARMA INC | 2010-09-29 | — | — | CN | disclosed |
| US-7772235-B2 | mGluR5 modulators | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-7772235-B2 | mGluR5 modulators | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-7772235-B2 | mGluR5 modulators | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-7691892-B2 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | ASTRAZENECA AB (SE) | 2008-05-29 | — | — | US | disclosed |
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | ASTRAZENECA AB (SE) | 2008-05-29 | — | — | US | disclosed |
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | ASTRAZENECA AB (SE) | 2008-05-29 | — | — | US | disclosed |
| WO-2008041075-A1 | MGLUR5 MODULATORS | ASTRAZENECA AB (SE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2007130824-A2 | FUSED HETEROCYLIC COMPOUNDS AND THEIR USE AS MGLUR5 MODULATORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070197549-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| CN-1918137-A | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | CN | disclosed |
| EP-1716125-A1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060004021-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| WO-2005080356-A1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004021-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM4 | GRM5 10/4885PKM 1183/4885MEN1 2336/4885 |
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | GLRA1, GRM1, GRM5 | GRM5 3/4885PKM 940/4885MEN1 3361/4885 |
| US-20070259860-A1 | MGluR5 modulators V | GRM5, GRIK5, GRM2 | GRM5 1/4885PKM 1276/4885MEN1 4264/4885 |
| US-20070197549-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM4 | GRM5 10/4885PKM 1245/4885MEN1 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.